---
title: "002907.SZ (002907.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002907.SZ/news.md"
symbol: "002907.SZ"
name: "002907.SZ"
parent: "https://longbridge.com/en/quote/002907.SZ.md"
datetime: "2026-05-21T17:55:15.177Z"
locales:
  - [en](https://longbridge.com/en/quote/002907.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002907.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002907.SZ/news.md)
---

# 002907.SZ (002907.SZ) — Related News

### [Pharscin Pharma: Injection-grade Methanesulfonic Acid Gabapentin Raw Material Drug Obtains Re-registration Approval](https://longbridge.com/en/news/286872647.md)
*2026-05-19T07:41:14.000Z*
> Pharscin Pharma announced that it recently received the "Chemical Raw Material Drug Re-registration Approval Notice" app

### [Pharscin Pharma: Ganju Bingmei tablets have completed domestic drug filing](https://longbridge.com/en/news/286063622.md)
*2026-05-12T08:48:18.000Z*
> Pharscin Pharma announced that the shelf life of its product Ganju Bingmei Tablets has been changed from 24 months to 36

### [Pharscin Pharma released its first-quarter performance, with a net profit attributable to the parent company of 32.7908 million yuan, a year-on-year decrease of 18.74%](https://longbridge.com/en/news/284565038.md)
*2026-04-29T11:57:04.000Z*
> Pharscin Pharma released its Q1 2026 earnings report, with operating revenue of 212 million yuan, a year-on-year decreas

### [Senxuan Pharma: Net profit in the first quarter was 47.0467 million yuan, a year-on-year increase of 62.05%](https://longbridge.com/en/news/284518832.md)
*2026-04-29T08:06:25.000Z*
> Senxuan Pharma announced that its revenue for the first quarter of 2026 was 160 million yuan, a year-on-year increase of

### [Pharscin Pharma: Net profit of 65.0868 million yuan in 2025, a year-on-year decrease of 15.17%](https://longbridge.com/en/news/283809975.md)
*2026-04-23T10:23:05.000Z*
> Pharscin Pharma announced that the operating revenue in 2025 is expected to be CNY 827 million, a year-on-year increase 

### [Pharscin Pharma: Shareholders holding more than 5% reduced their holdings by 2.4869 million shares](https://longbridge.com/en/news/280762322.md)
*2026-03-27T09:29:23.000Z*
> Pharscin Pharma announced that shareholder Liu Xiaoying, holding more than 5% of shares, will reduce her holdings by 2.4

### [Pharscin Pharma obtained the drug registration certificate for Buprenorphine Hydrochloride Tablets](https://longbridge.com/en/news/280130101.md)
*2026-03-23T09:07:03.000Z*
> Pharscin Pharma recently obtained the drug registration certificate for Buprenorphine Hydrochloride Tablets (5mg and 15m

### [Pharscin Pharma: Independent director Mr. Li Jiaming sadly passed away](https://longbridge.com/en/news/279754247.md)
*2026-03-19T09:05:07.000Z*
> Pharscin Pharma announced that Mr. Li Jiaming, the company's independent director, unfortunately passed away due to illn

### [KAISA GROUP plans to sell a 30.121% actual equity stake in Qinghai Pharmaceutical](https://longbridge.com/en/news/279628139.md)
*2026-03-18T15:10:58.000Z*
> KAISA GROUP announced that it plans to sell a 30.121% actual equity stake in Qinghai Pharmaceutical through its wholly-o

### [Pharscin Pharma: Clinical trial for HSN002066C1 tablet drug approved](https://longbridge.com/en/news/276711793.md)
*2026-02-24T09:35:04.000Z*
> Pharscin Pharma announced that its subsidiary Chongqing Pharscin Inno Biotechnology Co., Ltd. has received approval from